2024-10-24 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co., Inc. is a global pharmaceutical company that develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

1. **Relative Performance:** MRK has lagged behind the S&P 500 (VOO) in recent years, with a cumulative return of 64.96% compared to the S&P 500's 136.39%. This represents a negative 71.43% performance gap. The current relative divergence score of 14.05 indicates that MRK's performance is below the 90th percentile of its historical range relative to the S&P 500.

2. **Recent Price Action:** MRK's current price is 106.17. It is currently trading below its 5-day, 20-day, and 60-day moving averages, suggesting potential downward pressure.

| Moving Average | Price |
|---|---|
| 5-day | 108.28 |
| 20-day | 110.55 |
| 60-day | 113.86 |

3. **Technical Indicators:**

- **RSI (28.22):** The RSI is currently in oversold territory, suggesting that the stock may be due for a rebound.
- **PPO (-0.24):** The PPO is negative, indicating potential weakness in the stock.
- **Delta_Previous_Relative_Divergence (-15.64):** The negative value signifies a recent downward trend in MRK's relative performance against the S&P 500.
- **Expected_Return (0.0):** The expected return of 0% suggests that over the long term (2 years or more), MRK's potential returns may align with the S&P 500, with no expected outperformance.

4. **Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

MRK's most recent earnings report for Q2 2024 showed strong earnings per share (EPS) of $2.15, exceeding analyst expectations. Revenue also surpassed estimates at $16.11 billion. However, the company's overall financial performance remains under pressure due to generic competition for some of its key products.

5. **News and Recent Events:**

Recent market outlook for MRK remains mixed. While the company's strong Q2 earnings report offered a positive sentiment, concerns regarding generic competition and potential price pressure on key drugs like Keytruda continue to weigh on the stock. Some analysts remain optimistic about MRK's long-term growth potential, citing its robust pipeline of new drug candidates.  However, others express caution about the potential impact of generic competition on the company's profitability. 

**Overall Analysis:**

MRK's recent earnings performance has been positive, but the stock has underperformed the S&P 500 in the long term. The company faces challenges from generic competition, which could impact its future profitability. Technical indicators suggest potential downward pressure on the stock in the short term. Investors should monitor the impact of generic competition and the progress of MRK's new drug pipeline to assess the company's long-term growth potential.

**Disclaimer:** This analysis is for informational purposes only and should not be considered as investment advice. Always consult with a qualified financial professional before making any investment decisions.
